Breakthrough or Bust? Europe Bets on Its Boldest Device Pilot

EMA launches Europe's first formal fast-track pilot for breakthrough medical devices, opening a new route for medical innovators

6 May 2026

Europe's medicines regulator launched a pilot programme in April 2026 to create a dedicated fast-track pathway for breakthrough medical devices, marking the first formal scheme of its kind under EU law. It is designed to accelerate patient access to genuinely novel technologies across the bloc.

Manufacturers awarded "breakthrough" designation will receive priority scientific advice from EMA expert panels. To qualify, a device must demonstrate either a significant clinical advantage over existing treatments or the ability to address an unmet medical need. In its first phase, EMA will accept five devices, limited to class III and class IIb active devices.

Expansion is planned. Future phases are expected to cover in vitro diagnostics and additional device categories, as EMA assesses outcomes from the initial cohort.

Underpinning the scheme is guidance issued by the Medical Device Coordination Group in December 2025, alongside provisions embedded in EU medical device law, suggesting a durable policy commitment rather than a provisional measure.

Europe has until now lacked a structured equivalent to the US Food and Drug Administration's Breakthrough Device Programme, which has operated since 2018. Developers seeking expedited regulatory engagement in the EU were largely reliant on national-level processes, which varied considerably across member states.

For Brussels, this marks a deliberate shift in how it approaches medical innovation. Whether the scheme succeeds will depend in part on how many eligible developers apply, how quickly EMA can process designations, and whether the criteria prove workable in practice. Those questions will not be answered until Phase 1 concludes.